{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:15:42Z","timestamp":1794406542643,"version":"4.9.0"},"reference-count":224,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,1]]},"DOI":"10.1093\/eurheartj\/ehr158","type":"journal-article","created":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T23:04:34Z","timestamp":1309302274000},"page":"1769-1818","source":"Crossref","is-referenced-by-count":2154,"title":["ESC\/EAS Guidelines for the management of dyslipidaemias"],"prefix":"10.1093","volume":"32","author":[{"given":"\u017deljko","family":"Reiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. John","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Durrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Erdine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Halcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kjekshus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Perrone","family":"Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Vahanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Auricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ceconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"Deaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fagard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hasdai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhani","family":"Knuuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kolh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"McDonagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Poldermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan A.","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Sechtem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Anton","family":"Sirnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tendera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Torbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Vardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Widimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Document","family":"Reviewers:","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Poldermans","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Berkenboom","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"De Graaf","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Descamps","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Gotcheva","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Griffith","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido Francesco","family":"Guida","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadi","family":"Gulec","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Henkin","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Antero","family":"Kesaniemi","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lekakis","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios J.","family":"Manolis","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Marques-Vidal","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Masana","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McMurray","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mendes","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurab","family":"Pagava","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje","family":"Pedersen","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prescott","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quit\u00e9ria","family":"Rato","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sans","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Stalenhoef","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Wittekoek","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[{"name":"The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org\/guidelines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"2026080919343105600_EHR158C1","author":"Allender","year":"2008","journal-title":"European cardiovascular disease statistics"},{"key":"2026080919343105600_EHR158C2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0021-9150(94)90200-3","volume":"110","author":"Py\u00f6r\u00e4l\u00e4","year":"1994","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","article-title":"Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention","volume":"19","author":"Wood","year":"1998","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C4","first-page":"S1","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)","volume":"10","author":"De Backer","year":"2003","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080919343105600_EHR158C5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080919343105600_EHR158C6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.07.020","article-title":"Value and limitations of existing scores for the assessment of cardiovascular risk. A review for clinicians","volume":"54","author":"Cooney","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.109.852756","article-title":"Cardiovascular risk estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future?","volume":"122","author":"Cooney","year":"2010","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/HJR.0b013e3283213140","article-title":"How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators","volume":"16","author":"Cooney","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080919343105600_EHR158C11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.atherosclerosis.2009.02.041","article-title":"HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk","volume":"206","author":"Cooney","year":"2009","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C14","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C16","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"2026080919343105600_EHR158C17","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C18","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial","volume":"129","author":"Lewis","year":"1998","journal-title":"Ann Intern Med"},{"key":"2026080919343105600_EHR158C21","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS: Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C22","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C24","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C26","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C27","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than-average cholesterol concentrations, in the ANGLO-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C32","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C33","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C35","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C36","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C37","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Gissi-HF","year":"2008","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C40","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C41","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080919343105600_EHR158C42","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease","year":"2009","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C43","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"key":"2026080919343105600_EHR158C47","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00125-010-1806-9","article-title":"Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes","volume":"53","author":"Taskinen","year":"2010","journal-title":"Diabetologia"},{"key":"2026080919343105600_EHR158C48","article-title":"Meta-analysis of LDL-C, non-HDL-C and apo B as markers of cardiovascular risk","author":"Sniderman","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C50","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"2026080919343105600_EHR158C51","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C52","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Ann Med"},{"key":"2026080919343105600_EHR158C54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.mol.0000236367.42755.c1","article-title":"Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease","volume":"17","author":"Packard","year":"2006","journal-title":"Curr Opin Lipidol"},{"key":"2026080919343105600_EHR158C55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C56","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1469-1809.2007.00359.x","article-title":"The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk","volume":"71","author":"Drenos","year":"2007","journal-title":"Ann Hum Genet"},{"key":"2026080919343105600_EHR158C57","doi-asserted-by":"crossref","first-page":"a1095","DOI":"10.1136\/bmj.a1095","article-title":"Familial hypercholesterolaemia: summary of NICE guidance","volume":"337","author":"Wierzbicki","year":"2008","journal-title":"BMJ"},{"key":"2026080919343105600_EHR158C58","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2007.04.053","article-title":"Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)","volume":"100","author":"Murphy","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C59","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after intitiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C60","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1001\/jama.288.20.2569","article-title":"Optimal diets for prevention of coronary heart disease","volume":"288","author":"Hu","year":"2002","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C61","article-title":"Lipids, nutrition and coronary heart disease","volume-title":"Atherosclerosis and coronary artery disease","author":"Grundy","year":"1996"},{"key":"2026080919343105600_EHR158C62","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinternmed.2009.38","article-title":"A systematic review of the evidence supporting a causal link between dietary factors and coronary heart diseases","volume":"169","author":"Mente","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026080919343105600_EHR158C63","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C64","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ejcn.1602973","article-title":"Health effects of trans-fatty acids: experimental and observational evidence","volume":"63","author":"Mozaffarian","year":"2009","journal-title":"Eur J Clin Nutr"},{"key":"2026080919343105600_EHR158C65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ajcn\/40.2.351","article-title":"Serum cholesterol response to dietary cholesterol","volume":"40","author":"Keys","year":"1984","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C67","doi-asserted-by":"publisher","DOI":"10.3402\/fnr.v52io.1811","article-title":"Plant sterols\/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials","volume":"52","author":"Abumweis","year":"2008","journal-title":"Food Nutr Res"},{"key":"2026080919343105600_EHR158C68","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2008.06.019","article-title":"Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins","volume":"203","author":"Sirtori","year":"2009","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C70","article-title":"Exercise for overweight or obesity","volume":"4","author":"Shaw","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080919343105600_EHR158C71","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","article-title":"Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial","volume":"150","author":"Becker","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026080919343105600_EHR158C72","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C73","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.295.19.2262","article-title":"Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial","volume":"295","author":"Berthold","year":"2006","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C74","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"2026080919343105600_EHR158C75","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/ajcn\/72.5.1128","article-title":"Effects of dietary fructose on plasma lipids in healthy subjects","volume":"72","author":"Bantle","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C76","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1172\/JCI37385","article-title":"Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans","volume":"119","author":"Stanhope","year":"2009","journal-title":"J Clin Invest"},{"key":"2026080919343105600_EHR158C77","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C78","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.166.3.285","article-title":"Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials","volume":"166","author":"Nordmann","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026080919343105600_EHR158C79","doi-asserted-by":"crossref","first-page":"S1645","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"n-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/0003-4819-146-1-200701020-00004","article-title":"Alcohol consumption and risk for coronary heart disease among men with hypertension","volume":"146","author":"Beulens","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026080919343105600_EHR158C81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0021-9150(84)90193-X","article-title":"Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A control clinical trial","volume":"53","author":"Rabkin","year":"1984","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C82","doi-asserted-by":"crossref","first-page":"1509S","DOI":"10.3945\/ajcn.2009.27113E","article-title":"Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention","volume":"89","author":"Ordovas","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C83","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"NCEP Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults","year":"2001","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/026010600902000105","article-title":"Fish oil and the management of hypertriglyceridemia","volume":"20","author":"Mattar","year":"2009","journal-title":"Nutr Health"},{"key":"2026080919343105600_EHR158C85","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ajcn\/73.3.560","article-title":"Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women","volume":"73","author":"Liu","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"2026080919343105600_EHR158C86","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/er.2005-0013","article-title":"The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels","volume":"27","author":"Mooradian","year":"2006","journal-title":"Endocr Rev"},{"key":"2026080919343105600_EHR158C87","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004467.pub2","article-title":"Low glycaemic index diets for coronary heart disease","volume":"4","author":"Kelly","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080919343105600_EHR158C88","first-page":"I\/5","article-title":"Process for the assessment of scientific support for claims on foods: consensus on criteria","volume":"44","author":"PASSCLAIM","year":"2005","journal-title":"Eur J Nutr"},{"key":"2026080919343105600_EHR158C89","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.fct.2006.01.017","article-title":"Safety evaluation of phytosterol-esters. Part 9: results of a European post-launch monitoring programme","volume":"44","author":"Lea","year":"2006","journal-title":"Food Chem Toxicol"},{"key":"2026080919343105600_EHR158C90","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1210\/jc.2004-2350","article-title":"A critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations","volume":"91","author":"Dewell","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080919343105600_EHR158C91","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/VHRM.S3512","article-title":"Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: current understandings and future research priorities","volume":"4","author":"Rideout","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"2026080919343105600_EHR158C92","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 Fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0009-9236(99)70139-6","article-title":"Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors","volume":"65","author":"Mas","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"2026080919343105600_EHR158C94","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00044011-200525110-00003","article-title":"Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients","volume":"25","author":"Reiner","year":"2005","journal-title":"Clin Drug Investig"},{"key":"2026080919343105600_EHR158C95","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jada.2007.10.040","article-title":"Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet","volume":"108","author":"Swain","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"2026080919343105600_EHR158C97","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jama.295.6.655","article-title":"Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial","volume":"295","author":"Howard","year":"2006","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C98","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCULATIONAHA.108.191627","article-title":"Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention","volume":"119","author":"Harris","year":"2009","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C99","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.numecd.2007.10.004","article-title":"Non-pharmacological control of plasma cholesterol levels","volume":"18","author":"Poli","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026080919343105600_EHR158C100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1185\/03007990802631438","article-title":"Perspectives on low-density-lipoprotein cholesterol goal achievement","volume":"25","author":"Catapano","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2026080919343105600_EHR158C101","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C102","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population-based cohort study using the QResearch database","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"2026080919343105600_EHR158C103","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pds.1603","article-title":"The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care","volume":"17","author":"Garcia-Rodriguez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026080919343105600_EHR158C104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.amjcard.2007.07.057","article-title":"Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use","volume":"101","author":"Holoshitz","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","article-title":"Combination statin\u2013fibrate therapy: safety aspects","volume":"11","author":"Franssen","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2026080919343105600_EHR158C106","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C107","doi-asserted-by":"crossref","first-page":"61C","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C108","doi-asserted-by":"crossref","first-page":"14C","DOI":"10.1016\/0002-9149(84)90851-8","article-title":"Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial","volume":"54","author":"Tyroler","year":"1984","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C109","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1089\/met.2010.0087","article-title":"Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus","volume":"8","author":"Levy P","year":"2010","journal-title":"Metab Syndr Relat Disord"},{"key":"2026080919343105600_EHR158C110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence","volume":"12","author":"Fonseca","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"2026080919343105600_EHR158C111","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"SHARP Collaborative Group","year":"2010","journal-title":"Am Heart J"},{"key":"2026080919343105600_EHR158C112","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2026080919343105600_EHR158C113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1472-8206.2009.00764.x","article-title":"Combined therapy in the treatment of dyslipidemia","volume":"24","author":"Reiner","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"2026080919343105600_EHR158C114","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.amjcard.2009.07.035","article-title":"Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis treatment study (FATS), the HDL-Atherosclerosis treatment study (HATS) and the Armed Forces regression Study (AFREGS)","volume":"104","author":"Zhao","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.clinthera.2010.04.014","article-title":"Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind, controlled trial","volume":"32","author":"Huijgen","year":"2010","journal-title":"Clin Ther"},{"key":"2026080919343105600_EHR158C116","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C117","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C118","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidaemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C119","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C121","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C122","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2026080919343105600_EHR158C123","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"2026080919343105600_EHR158C124","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C126","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study","volume":"102","author":"The BIP Study Group","year":"2000","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C127","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C128","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C129","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/ATVBAHA.108.178228","article-title":"Relationships of HDL cholesterol, apoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate","volume":"29","author":"Taskinen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080919343105600_EHR158C130","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C131","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C132","doi-asserted-by":"crossref","first-page":"58B","DOI":"10.1016\/j.amjcard.2008.02.039","article-title":"Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk","volume":"101","author":"Brown","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C133","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2009.06.036","article-title":"Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study","volume":"54","author":"Lee","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C134","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS trial. Final results and the impact of medication adherence, dose and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C136","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C137","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.38755.366331.2F","article-title":"Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review","volume":"332","author":"Hooper","year":"2006","journal-title":"BMJ"},{"key":"2026080919343105600_EHR158C138","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C139","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidaemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C141","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"The ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C142","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C143","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidaemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C144","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C145","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C146","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding rescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"key":"2026080919343105600_EHR158C147","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C148","article-title":"Triglyceride-rich lipoprotein and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","author":"The European Atherosclerosis Society Consensus Panel","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C149","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C150","first-page":"682","article-title":"The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7,098 patients with dyslipidaemia","volume":"6","author":"Poulter","year":"1999","journal-title":"Br J Cardiol"},{"key":"2026080919343105600_EHR158C151","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C152","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C153","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C154","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veenkamp","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080919343105600_EHR158C155","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"key":"2026080919343105600_EHR158C156","volume-title":"Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia.","author":"DeMott","year":"2008"},{"key":"2026080919343105600_EHR158C157","volume-title":"Familial hypercholesterolemia: Report of a second WHO consultation","author":"World Health Organization, Human Genetics Programme","year":"1999"},{"key":"2026080919343105600_EHR158C158","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin Vasc Med"},{"key":"2026080919343105600_EHR158C159","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Genet"},{"key":"2026080919343105600_EHR158C160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1258\/acb.2009.009076","article-title":"Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients","volume":"47","author":"Whittall","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"2026080919343105600_EHR158C161","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11936-009-0029-1","article-title":"Low-density lipoprotein apheresis as a treatment for hyperlipidaemia","volume":"11","author":"Mehta","year":"2009","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026080919343105600_EHR158C162","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00043798-200204000-00001","article-title":"Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study","volume":"9","author":"Jonsdottir","year":"2002","journal-title":"J Cardiovasc Risk"},{"key":"2026080919343105600_EHR158C163","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2008.08.001","article-title":"Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis","volume":"138","author":"Petretta","year":"2010","journal-title":"Int J Cardiol"},{"key":"2026080919343105600_EHR158C164","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1001\/jama.291.18.2243","article-title":"Drug treatment of hyperlipidaemia in women","volume":"291","author":"Walsh","year":"2004","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacc.2008.09.042","article-title":"Contraceptive hormone use and cardiovascular disease","volume":"53","author":"Shufelt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C166","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C167","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2010.01.013","article-title":"Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment","volume":"55","author":"Gransbo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C168","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C169","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ahj.2007.01.003","article-title":"Ten-year risk of cardiovascular indidence related to diabetes, prediabetes, and the metabolic syndrome","volume":"153","author":"Liu","year":"2007","journal-title":"Am Heart J"},{"key":"2026080919343105600_EHR158C170","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C171","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080919343105600_EHR158C172","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"2026080919343105600_EHR158C173","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/dc07-1117","article-title":"Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study","volume":"31","author":"IIanne-Parikka","year":"2008","journal-title":"Diabetes Care"},{"key":"2026080919343105600_EHR158C174","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S","volume":"104","author":"Ballantyne","year":"2001","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus\u2014a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026080919343105600_EHR158C176","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C177","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"2026080919343105600_EHR158C178","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial","volume":"354","author":"GISSI-Prevenzione Investigators","year":"1999","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C179","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary interventions: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"2026080919343105600_EHR158C181","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026080919343105600_EHR158C182","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effects of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the Treating to New Targets (TNT) study","volume":"115","author":"Kush","year":"2007","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C183","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C184","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C185","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2003.08.066","article-title":"Effect of statins on the progression of bioprosthetic aortic valve degeneration","volume":"92","author":"Antonini-Canterin","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C186","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026080919343105600_EHR158C187","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026080919343105600_EHR158C188","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/art.11241","article-title":"Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus","volume":"48","author":"Thorburn","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026080919343105600_EHR158C189","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.ajkd.2006.09.017","article-title":"The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment","volume":"49","author":"Hyre","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026080919343105600_EHR158C190","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"de Jager","year":"2009","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C191","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2005070779","article-title":"Effect of pravastatin in people with diabetes and chronic kidney disease","volume":"16","author":"Tonelli","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2026080919343105600_EHR158C192","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C193","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026080919343105600_EHR158C194","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria","volume":"145","author":"Douglas","year":"2006","journal-title":"Ann Intern Med"},{"key":"2026080919343105600_EHR158C195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C196","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C197","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient part IV: drug\u2013drug interactions","volume":"111","author":"Page","year":"2005","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C198","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","volume":"2","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080919343105600_EHR158C199","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e318198d7d0","article-title":"The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin","volume":"87","author":"Shaw","year":"2009","journal-title":"Transplantation"},{"key":"2026080919343105600_EHR158C200","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1001\/archinte.163.18.2157","article-title":"Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease","volume":"163","author":"Mc Dermott","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026080919343105600_EHR158C201","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0890-5096(06)61452-0","article-title":"Basic data concerning associated coronary disease in peripheral vascular patients","volume":"1","author":"Hertzer","year":"1987","journal-title":"Ann Vasc Surg"},{"key":"2026080919343105600_EHR158C202","article-title":"Lipid lowering for peripheral arterial disease of the lower limb","volume":"4","author":"Maxwell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080919343105600_EHR158C203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2004.08.005","article-title":"Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis","volume":"177","author":"Kang","year":"2004","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C204","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jvs.2007.03.035","article-title":"Statins: an essential component in the management of carotid artery disease","volume":"46","author":"Paraskevas","year":"2007","journal-title":"J Vasc Surg"},{"key":"2026080919343105600_EHR158C205","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","article-title":"Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis","volume":"35","author":"Amarenco","year":"2004","journal-title":"Stroke"},{"key":"2026080919343105600_EHR158C206","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.amjcard.2005.05.070","article-title":"Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease","volume":"96","author":"Tedeschi-Reiner","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C207","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ejvs.2006.03.009","article-title":"Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?","volume":"32","author":"Paraskevas","year":"2006","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026080919343105600_EHR158C208","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jvs.2004.01.004","article-title":"Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial","volume":"39","author":"Durazzo","year":"2004","journal-title":"J Vasc Surg"},{"key":"2026080919343105600_EHR158C209","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMoa0808207","article-title":"Fluvastatin and perioperative events in patients undergoing vascular surgery","volume":"361","author":"Schouten","year":"2009","journal-title":"N Engl J Med"},{"key":"2026080919343105600_EHR158C210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"2026080919343105600_EHR158C211","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.CIR.103.3.387","article-title":"Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) project","volume":"103","author":"Byington","year":"2001","journal-title":"Circulation"},{"key":"2026080919343105600_EHR158C212","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1468-1293.2006.00400.x","article-title":"Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study","volume":"7","author":"Glass","year":"2006","journal-title":"HIV Med"},{"key":"2026080919343105600_EHR158C213","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00002030-200304110-00010","article-title":"Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART","volume":"17","author":"Calza","year":"2003","journal-title":"AIDS"},{"key":"2026080919343105600_EHR158C214","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV Med"},{"key":"2026080919343105600_EHR158C215","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/135965350701200711","article-title":"Pharmacokinetics and pharmacodynamics of combined use of lopinavir\/ritonavir and rosuvastatin in HIV-infected patients","volume":"12","author":"Van der Lee","year":"2007","journal-title":"Antivir Ther"},{"key":"2026080919343105600_EHR158C216","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/592116","article-title":"Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy","volume":"47","author":"Wohl","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026080919343105600_EHR158C217","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.amjmed.2008.02.031","article-title":"Lowering LDL cholesterol in adults: a prospective, community-based practice initiative","volume":"121","author":"Coodley","year":"2008","journal-title":"Am J Med"},{"key":"2026080919343105600_EHR158C218","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"2026080919343105600_EHR158C219","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026080919343105600_EHR158C220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"2026080919343105600_EHR158C221","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0140-6736(08)60868-5","article-title":"Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial","volume":"371","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"2026080919343105600_EHR158C222","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ypmed.2010.09.015","article-title":"Public perceptions of cardiovascular risk factors: the PERCRO survey","volume":"51","author":"Reiner","year":"2010","journal-title":"Prev Med"},{"key":"2026080919343105600_EHR158C223","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.atherosclerosis.2010.09.014","article-title":"Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey","volume":"213","author":"Reiner","year":"2010","journal-title":"Atherosclerosis"},{"key":"2026080919343105600_EHR158C224","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1532-5415.2000.tb04691.x","article-title":"Selecting target conditions for quality of care improvement in vulnerable older adults","volume":"48","author":"Sloss","year":"2000","journal-title":"J Am Geriatr Soc"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/32\/14\/1769\/70578461\/eurheartj_32_14_1769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/32\/14\/1769\/70578461\/eurheartj_32_14_1769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T23:34:58Z","timestamp":1786318498000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/32\/14\/1769\/528352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":224,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2011,1,1]]},"published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehr158","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718277728.793490990","asserted-by":"object"}]},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,7]]},"published":{"date-parts":[[2011,1,1]]}}}